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Time to Throw Out the Gadolinium?*Reza Nezafat, PHDSEE PAGE 1019C ardiac magnetic resonance (CMR) late gado-linium enhancement (LGE) (1) is the currentclinical gold standard modality for evalua-
tion of focal ﬁbrosis and scar in patients with an
ischemic or a nonischemic cardiomyopathy. LGE re-
quires administration of an exogenous gadolinium-
based contrast agent, which accumulates in the
scar region. LGE imaging is commonly performed
using an inversion recovery sequence 10 to 20 min
after contrast injection to visualize myocardial
scar. Patients are often referred for CMR examina-
tion for assessment of scar and myocardial perfu-
sion, which both require gadolinium. As a result,
over 80% of CMR examinations are performed with
gadolinium.
Gadolinium contrast agents were considered very
safe and were commonly used at double and even
triple doses. In 2006, there were reports of nephro-
genic systemic ﬁbrosis, a systemic and potentially
fatal scleroderma-like illness, in patients with mod-
erate to severe renal dysfunction who had received
gadolinium (2,3). However, with the new restriction
for the use of gadolinium contrast in patients with
compromised renal function, no recent cases of
nephrogenic systemic ﬁbrosis have been reported.
Most patients now undergoing contrast CMR must
undergo additional testing for kidney function.
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have been several recent reports of progressive in-
creases in T1-weighted magnetic resonance signal in
various central nervous system structures following
repeated gadolinium administration (4). Although the
clinical signiﬁcance of accumulation of the residual
gadolinium in brain and bone is not yet understood,
we should be more cautious in administering contrast
agents and should try to avoid unnecessary contrast
administration even in patients with normal renal
function.
Myocardial T1 mapping has emerged as a novel
CMR sequence for evaluation of interstitial diffuse
ﬁbrosis. Initial T1 mapping studies focused on short-
ened post-contrast myocardial T1 values as a marker
of ﬁbrosis. However, there are many confounders of
post-contrast T1 measurements, such as contrast
dose, timing, and type, diminishing the enthusiasm
for post-contrast T1 mapping. Instead, native T1
mapping (i.e., T1 imaging without a contrast agent)
has emerged as the preferred approach to quantify
myocardial T1.In this issue of iJACC, Kali et al. (5) investigated
the utility of native myocardial T1 mapping at 3-T for
detection of myocardial scar in a small cohort of pa-
tients with chronic ST-segment elevation and non–
ST-segment elevation myocardial infarction. T1 data
were compared with LGE, which is considered the
gold standard. Although the analysis was performed
by blinded individuals, all subjects were known to
have a chronic infarction. Infarct size and trans-
murality using a signal thresholding were similar for
native T1 maps and LGE images. The sensitivity and
speciﬁcity for detecting chronic infarct quantitatively
measured with thresholding were in the high 80s and
90s. However, sensitivity was only moderate (low
60%) for visual detection of infarct on native T1 maps.
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1032The results of the study are encouraging and high-
light the potential of native T1 mapping for the
detection of chronic infarction. However, the more
modest sensitivity of visual assessment suggests that
native T1 mapping will not replace LGE imaging. With
chronic infarction, LGE is usually readily appreciated
and there is very little ambiguity in the clinical
interpretation of LGE. Several quantitative scar
delineation techniques for LGE, such as thresholding,
have been proposed and used in research studies, but
quantitative LGE scar delineation has not made it
into clinical practice due to low reproducibility and
lack of consensus on a standard method of segmen-
tation. This challenge also applies to segmentation of
native T1. There are 2 factors that can affect these
measurements: 1) identiﬁcation of remote normal
region; and 2) selection of thresholding value.
Over the past several decades, there have been
sustained efforts by magnetic resonance scientists to
accurately and reproducibly measure tissue relaxa-
tion parameters including T1 and T2. However, im-
aging and physiological confounders have limited
our ability to accurately measure these tissue pa-
rameters. With recent advances in CMR, native T1
mapping has re-emerged again as a “novel” imaging
marker (6). There have been numerous T1 mapping
sequences, often with confusing acronyms, but
fundamentally with a similar concept of sampling
the recovery of magnetization to estimate native T1
value. Despite technical challenges in robust mea-
surement of T1 values, the clinical signiﬁcance of
abnormal T1 values remain unknown and under
extensive investigation by many groups. But, are we
simply adding another number to our long list of
measures that CMR provides without truly affecting
patient management? Despite many recent publica-
tions and sometimes contradictory data, it is still too
early to judge how and in which disease native T1
mapping will affect patient management. High vari-
ability in T1 measurements often results in signiﬁ-
cant overlap in measurements between different
myopathies, which make this technique of limiteduse in management of an individual patient. It also
remains to be seen if technical innovation to simul-
taneously improve accuracy, reproducibility, and
precision of T1 measurements (7) can further push
this ﬁeld forward—enabling patient-speciﬁc diag-
nosis and prognosis.
The notion of replacing LGE with native T1 map-
ping is enticing, but current data are limited to sup-
port this (5,8,9). First, although the native T1 of
infarcted myocardium differs from healthy myocar-
dium, T1 values are inﬂuenced by imaging and phys-
iological confounders. Second, many of the current T1
mapping sequences, including the MOLLI sequence
(10) used by these investigators, are sensitive to
myocardial T2 as well; therefore, edema and inﬂam-
mation could affect T1 measurements (although not in
the setting of chronic infarction). Third, similar to the
challenges of LGE segmentation, determining a
threshold value for abnormal native T1 and a remote
normal region will be difﬁcult. Finally, despite the
growth in installation of 3-T CMR scanners, the ma-
jority of clinical CMR scanners are 1.5-T.
In summary, for patients with renal dysfunction,
there is an unmet clinical need for non–contrast-
based scar imaging. With the emerging data on
retention of gadolinium in the central nervous sys-
tem as well as the additional cost of gadolinium, a
noncontrast sequence for scar detection will be a
great asset in our CMR imaging toolbox. Kali et al. (5)
provide the proof-of-concept of potential of 3-T
native T1 mapping as a replacement for LGE. How-
ever, further technical challenges and larger multi-
center, multivendor studies are needed to better
understand the utility of native T1 in detecting
chronic infarction.
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